CareDx (CDNA) Earnings Date & Reports

Key Takeaways

• CareDx, Inc. (Nasdaq: CDNA) is scheduled to report its third quarter 2026 financial results after the market close on Thursday, October 29, 2026.
• Wall Street consensus calls for non-GAAP earnings per share (EPS) of roughly $0.24 and revenue of approximately $123 million for the quarter.
• CareDx has beaten consensus revenue estimates in each of its last four quarters, and exceeded EPS estimates in three of those periods.
• Management raised its full-year 2026 outlook to revenue of $490 million to $500 million and adjusted EBITDA of $66 million to $78 million.
• Investors will closely track testing services volume, average revenue per test, and progress integrating the recently acquired Naveris oncology business.

Earnings Context and Why It Matters

CareDx has become a central name in precision diagnostics for transplant patients, driven by its AlloSure and HeartCare monitoring tests. The upcoming quarterly earnings report matters because it will show whether the company can sustain its recent momentum following a series of strong results and an upgraded full-year outlook. The company has also undergone significant transformation in 2026, completing the divestiture of its Lab Products business and acquiring Naveris to enter specialty oncology. With the stock having surged after its last report, this earnings release is a key test of whether accelerating testing services revenue, improving margins, and disciplined cost control can continue to support investor confidence.

Earnings Expectations

Analysts expect CareDx to report non-GAAP EPS of approximately $0.24 on revenue near $123 million for the third quarter of 2026. For context, the company posted non-GAAP EPS of $0.37 and revenue of $131.9 million in the second quarter, far exceeding consensus estimates and helping send shares sharply higher the following day. In the prior-year third quarter, CareDx reported revenue of about $100 million.

Several key metrics will be in focus beyond the headline numbers. Testing services volume, which has grown roughly 17% year-over-year in recent quarters, remains the primary growth engine. Analysts will also watch average revenue per test and patient and digital solutions revenue, which grew 50% year-over-year in the second quarter. Management guidance and commentary on the MolDx (Molecular Diagnostics) reimbursement environment, the Naveris integration, and the rollout of pipeline programs such as AlloSure liver will be equally important.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven moves across the diagnostics sector, the AI Screener can help surface relevant setups before and after key reporting dates.

Market Reaction and Investor Sentiment

Sentiment heading into the third quarter report is generally constructive. CareDx shares climbed significantly after its second quarter results, and the company's decision to raise full-year guidance has reinforced a positive narrative around testing services growth and operational leverage. Investors appear to be pricing in continued double-digit revenue expansion and further margin improvement.

That said, risks remain. The stock's recent strength raises the bar for the print, and any softness in testing volume, average revenue per test, or the full-year outlook could trigger volatility. External factors, including the timing of reimbursement decisions from the MolDx Group and broader transplant procedure volumes, are also key swing factors that could shape the immediate post-earnings reaction.

Forward Outlook and Key Factors to Monitor

Looking beyond the third quarter, investors will focus on whether CareDx can deliver against its raised full-year 2026 targets of $490 million to $500 million in revenue and $66 million to $78 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). Sustaining testing services volume growth and stable average revenue per test will be central to that goal.

The integration of Naveris is another important theme. The acquisition expanded CareDx into specialty oncology, and commentary on the timeline for commercial expansion and any new indications will be closely watched. Management has indicated it will apply its repeat-testing and workflow expertise to accelerate growth in this adjacent market.

Finally, pipeline progress matters for the longer-term story. Programs such as AlloSure liver, HistoMap kidney, and the Alaheme cell therapy initiative represent potential avenues to expand the company's total addressable market. Investors should monitor clinical milestones, reimbursement updates, and cost trends, as these factors will help determine whether the company's recent growth trajectory is durable.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations